Drug Profile

CDX 014

Alternative Names: CDX-014; CR 014-vcMMAE

Latest Information Update: 15 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Amgen; CuraGen Corporation
Developer Celldex Therapeutics Inc
Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
Mechanism of Action Membrane protein inhibitors; T cell activation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Ovarian cancer; Renal cell carcinoma

Most Recent Events

14 Dec 2023 Seagen has been acquired by Pfizer
08 Oct 2020 Seattle Genetics is now called Seagen
17 May 2018 Discontinued - Phase-I/II for Ovarian cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com